Sangui Biotech International, Inc. Announces Revenue Results for the First Half Ended December 31, 2017; Provides Sales Guidance for the Calendar Year 2018
January 19, 2018 at 04:27 am
Share
Sangui Biotech International, Inc. announced revenue results for the first half ended December 31, 2017. The company achieved revenues in the amount of approximately USD 54,000 from license fees in the first half year of fiscal 2018 ended December 31, 2017. Due to increased revenues of the wound spray Granulox, the resulting licensing income in the first half year increased by 54% compared to the same period of the previous year.
The company expects to see a significant increase in total sales for the calendar year 2018.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
Sangui Biotech International, Inc. Announces Revenue Results for the First Half Ended December 31, 2017; Provides Sales Guidance for the Calendar Year 2018
SANGUI BIOTECH INTERNATIONAL, INC. 
